Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

Study Overview

This research study is studying a drug that may help decrease the chances of relapse after Allogeneic Stem Cell transplantation for Acute Myeloid Leukemia. The name of the study drug involved in this study is:

  • Ruxolitinib

Study Description

Phase II Study of Maintenance Ruxolitinib after Allogeneic Stem Cell Transplantation for Older Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)

  • Identifier: NCT03286530
  • Protocol Number: 17-273
  • Principal Investigator: Myrna Nahas

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000